Connect with us

News

The vital role of AI skills in women’s career advancement and practical steps to begin

By Chaitra Vedullapalli, co-founder and president of Women in Cloud

Published

on

With the unparalleled level of noise, confusion, and fear surrounding AI it can become overwhelming to parse out what news is sensationalised and what is true, especially when it comes to AI and the impact it has on the jobs market. 

Contrary to what some fear-mongering articles have shared, according to the 2024 Work Trend Index from Microsoft and LinkedIn, tech leaders are worried about whether or not they will be able to fill key roles. 

Over the past eight years companies have hired up to 323 per cent of technical AI talent.

Now they’re turning their sights to non-technical talent with AI aptitude. This means they’re actively seeking new team members with the skills to use generative AI tools like ChatGPT and Copilot. 

As the founder of an organisation committed to generating $1B in new economic access for women and allies in tech by 2030, I can see a huge opportunity for diverse women and allies in tech to land new roles and as a result speed up the closure of the representation and gender gap.

How?

By actively preparing, pursuing and learning new skill sets and earning the credentials to prove it. 

To get ahead of this anticipated hiring wave, here are three reasons to pursue certifications and credentials for real-world skill sets that address critical business problems right now:

  1. Career Advancement in an AI-centric Economy: By gaining relevant project-based, you will enhance your confidence and increase your trust level with current managers as well as hiring managers. In an AI-driven economy, possessing AI skills becomes imperative for career progression. Investing time in developing these skill sets now ensures you are well-positioned to seize opportunities and contribute meaningfully to any organisation’s growth.
  2. Future-proofing Skillsets for AI Opportunities: Investing in AI skills today equips you with future-proof capabilities essential for navigating the evolving job market. By seizing AI opportunities now, individuals ensure they stay ahead of the curve and remain adaptable and competitive in an AI-driven environment.
  3. Accelerated Skill Development and Enhanced Professional Profile: Pursuing scenario-focused credentials enables individuals to achieve credentials faster, accelerating their skill development journey. By showcasing project-based proficiency, individuals will differentiate themselves and demonstrate their ability to apply theoretical knowledge to real-world situations. 

Rather than staying stuck in fear of how AI may change the jobs landscape, women everywhere need to reframe this shift as an invitation to enter tech for the first time or scale to a new role they’ve been aiming for. 

It’s no secret that the entry barrier for diverse and underrepresented communities in tech is often much greater than not.

However, one of the most overlooked and underutilised ways to mitigate this is obtaining certifications and verifiable credentials for skillsets companies will have as requirements when hiring for new roles. 

A great place to start your journey is with the #WICxSkillsReadyChallenge.

This initiative leverages Microsoft Applied Skills, offering a new verifiable credential that validates specific real-world skill sets that address critical business problems.

This new skill set can be earned through interactive lab-based assessments on the Microsoft Learn platform in weeks.

During this challenge participants will earn Microsoft Applied Skills credentials in AI in just weeks, have the opportunity to win exciting prizes every month, receive exclusive invitations for spotlights, speak at events, network with recruiters, and connect and become a part of the record-setting WIC community.

We encourage all genders to apply, with priority given to women across all global markets and historically underrepresented populations.

I invite you to apply here today, it’s valued at $4500 and it is 100 per cent free.

The change I’ve witnessed from women taking advantage of opportunities like this is drastic.

Two journeys particularly stand out to me, those of Shammah Saratu Yaro and Caleb Yeboah have been inspiring and transformative.

The scholarships have helped them attain certifications, and access free vouchers enabling them to take exams and land new DevSecOps roles, accelerating their career growth and leadership opportunities. 

You can begin your journey today.

Setting aside a few weeks to continue or begin your personal and professional development with applicable skills in the tech industry is a lifelong practice that will keep you ahead of the curve, for AI and beyond.

Chaitra Vedullapalli Bio:

Chaitra Vedullapalli is the award-winning Co-Founder and CMO of Meylah and Co-Founder and President of Women In Cloud.

In her 26 years in tech, Chaitra has driven billion-dollar expansions for both Microsoft and Oracle, has been recognised with the Forbes 1000 Next Entrepreneur title, Microsoft Women’s Leadership Award, set a new Guinness World Record, and is listed as one of 100 Most Innovative MarTech Leaders by World Marketing Congress.

Presenting before the UN, at TedX, Grace Hopper Celebration, and Microsoft Inspire, she is a purpose-driven, strategic, high-growth thought leader who seamlessly bridges business and technology to help companies globally scale and drive digital economic development. 

Her mission is to generate $1B in new net economic access for women entrepreneurs and professionals by 2030 through global partnerships with corporations, community leaders, and policymakers.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

News

‘Long waiting lists and patchy care provision’- NHS-funded IVF cycles fall to 14-year low

NHS-funded IVF procedures dropped to 27 per cent in 2022 from 40 per cent in 2012, new data shows

Published

on

The proportion of NHS-funded IVF cycles in the UK has fallen to the lowest level for 14 years, leaving fertility patients either unable to access treatment or forced to go private.

Some 27 per cent of IVF cycles were funded by the NHS in 2022, the lowest figure since 2008 and a sharp fall on the 40 per cent which it provided in 2012, according to the latest annual report by the Human Fertilisation and Embryology Authority (HFEA).

The number of NHS-funded cycles of IVF fell by 17 per cent in England, 16 per cent in Wales and seven per cent in Scotland between 2019 and 2022, the report showed. The East Midlands of England saw the biggest fall during that time, down 48 per cent.

The regulator said the fall may be being fuelled by the rise in NHS waiting lists, meaning it is taking longer for many patients to see a specialist in the first place.

Such delays can mean that women seeking help with fertility lose their window for treatment, as the chances of success fall.

Julia Chain, chair of the HFEA, said: “Our data shows the average age of patients starting treatment for the first time is now nearly six years older than the average age at which women in England and Wales gave birth to their first child.

“There are several possible factors for this including the knock-on effect of delays across the NHS due to the COVID-19 pandemic, particularly in gynaecology, which has likely led to delays in some patients accessing fertility services.”

The higher average age, Chain said, may also relate to difficulty in funding fertility treatment, owing to recent increases in the cost of living, a fall in the proportion of NHS-funded IVF cycles and increased waiting times for further investigations before accessing NHS-funded treatment.

Leila Thabet, general manager at Maven Clinic, told Femtech World: “Today’s figures highlight what many of us working in the field of women’s health have known for some time – fertility treatment is extremely challenging to access on the NHS.

“NHS IVF treatment is subject to long waiting lists and patchy care provision, often with inadequate support for the emotional toll the treatment takes.

“Women undergoing IVF will all need different types and levels of support as every IVF journey is different. This personalised treatment is not something the NHS is set up to provide, so even where women are lucky enough to benefit from NHS fertility treatment, they may need to turn to other providers for additional physical and emotional support.”

She added: “Women going through IVF often describe it as all consuming. It impacts every aspect of your life – physically, emotionally and practically. Juggling IVF treatment and a career are notoriously hard, for example. Add the huge financial toll, and we can clearly see why fertility treatment is life changing in every sense, no matter the outcome.”

Continue Reading

News

Future Fertility and IVI RMA Global Research Alliance forge landmark commercial partnership to raise standard of care in egg quality assessment

Published

on

Future Fertility, the leader in AI-powered oocyte quality assessment, and IVI RMA Global, the world’s leading reproductive medicine group, are excited to announce their new strategic commercial partnership.

Under this landmark agreement, Future Fertility’s VIOLET™ tool will be integrated into every egg freezing cycle at IVI RMA’s clinics across Europe and Latin America. Both companies will also collaborate to determine how this technology can be used to assess donor egg quality to provide greater transparency and precision in egg donation treatments.

IVI RMA is renowned for its scientific leadership and adoption of cutting-edge technology to advance patient care. This collaboration marks IVI RMA’s first large-scale AI technology partnership and is the most extensive clinic network partnership to date for Future Fertility.

Future Fertility has rapidly gained adoption within the fertility industry, with its oocyte assessment tools installed in over 100 clinics across more than 25 countries. Its seamless integration with various laboratory setups, from time-lapse to microscope-only environments, and unparalleled patient-facing oocyte quality reports have been the drivers of this momentum.

As the company’s dataset has grown to over 150,000 oocyte images and associated reproductive outcomes, the adoption of these tools is driving the creation of a standard of care for oocyte quality assessment.

“Future Fertility’s AI tools allow our clinics to evaluate oocyte quality with an unprecedented level of objectivity and data-driven precision,” said Prof. Laura Rienzi, head of innovation at IVI RMA.

“Their dedication to thorough clinical validation and peer-reviewed scientific publications provides us with evidence that these tools hold the potential to improve our lab processes, treatment planning and patient experience across our network.”

“Partnering with IVI RMA is an incredibly exciting milestone for us,” said Christy Prada, CEO of Future Fertility.

“This is a true testament to the value of our oocyte reports from an extremely prestigious leader in clinical care, and a strong validation of our scientific approach from the largest clinical network in fertility care globally.”

Empowering egg freezing patients with personalised insights

Historically, fertility specialists estimated an egg freezing patient’s chance of success based on age and the number of mature eggs retrieved.

Future Fertility’s deep learning model personalises fertility care by evaluating each egg’s unique likelihood of developing into a blastocyst based on its image. VIOLET™ reports also provide each patient with their personal chance of achieving a live birth from the eggs they’ve frozen.

Dr Antonio Requena, IVI RMA’s group medical director, emphasised the impact on patient care: “These individualised insights allow our clinical team to customise treatment plans to each patient’s specific needs, offering essential clarity on treatment expectations and improving patient counselling for future steps.”

“The current standard of care in reproductive medicine includes standardised methods to evaluate sperm, embryos, and the endometrium – but not the egg,” says Dr Dan Nayot, chief medical officer and co-founder at Future Fertility.

“Our team has been able to address this gap with AI so that patients and their fertility care teams can be empowered with precise information to make more-informed decisions along the path to parenthood.”

Long-term scientific partnership and expanded commercial collaboration

IVI RMA, ever committed to the scientific advancement of reproductive medicine, first began utilising Future Fertility’s tools in egg quality-focused research at its leading clinics in Spain in 2022.

Dr Marcos Meseguer, scientific director at IVI Valencia, highlighted the benefits of these tools in driving new avenues for investigation: “Future Fertility’s oocyte AI has created the opportunity for us to study and better understand the impact of different clinical approaches on egg quality.

“As the first player to develop this type of solution, they are paving the way for the industry to evolve thinking on the role of egg quality in treatment plans.”

His team presented their scientific findings at last year’s American Society of Reproductive Medicine conference in New Orleans, confirming the ability of VIOLET™ to predict fertilisation, blastocyst and live birth outcomes from oocyte images taken within the lab.

Other IVI RMA clinics under the GINEFIV, GINEMED and GENERA brands have been using VIOLET™ and MAGENTA™ in their scientific research for the past year and a half, assessing the role of AI in evaluating donor egg quality, enhancing transparency for recipients, and optimising donor egg screening.

“We were early believers in the importance of oocyte quality with respect to reproductive success,” said Dr Danilo Cimadomo, director of innovation in embryology at IVI RMA Italia.

“Future Fertility’s AI tools hold potential for improving our research projects by bringing objectivity into our efforts to better understand egg donor cycles.”

The progression of this enduring partnership from experimental roots to commercial adoption is indicative of the growing affirmation of Future Fertility’s technology worldwide.

Rafael Gonzalez, head of global sales and commercial strategy at Future Fertility, commented: “Our commercial traction has been remarkable across the countries we operate in.

“This new partnership with IVI RMA Global is the culmination of our long-time collaboration and is now empowering patients globally with more precise insights into their fertility treatment options.”

Continue Reading

News

Women with endometriosis face fourfold higher risk of ovarian cancer, study finds

Published

on

The risk of developing ovarian cancer could jump about fourfold among women with endometriosis compared with women without the condition, a new study has found.

A landmark study from researchers at the University of Utah and Boston University Chobanian & Avedisian School of Medicine found that women with severe endometriosis are 10 times more likely to get ovarian cancer compared to women who do not have the disease.

Prior studies have shown a causal connection between endometriosis and ovarian cancer but in using the Utah Population Database, a repository of linked health records housed at Huntsman Cancer Institute at the University of Utah, investigators were able to analyse the incidence rates of different types of endometriosis and subtypes of ovarian cancer for the first time.

Their research, which included a cohort of over 78,000 women with endometriosis, found that women with severe forms — either deep infiltrating endometriosis, ovarian endometriomas or both — have an overall ovarian cancer risk that’s “markedly increased,” at about 9.7 times higher, relative to women without endometriosis.

Women with deep infiltrating endometriosis, ovarian endometriomas or both, on the other hand, appear to face nearly 19 times the risk of type I ovarian cancer, which tends to grow more slowly, compared with women without endometriosis, according to the study.

In their calculations, researchers also found that women with any kind of endometriosis have a 4.2-fold risk of developing ovarian cancer compared to those who do not.

“These are really important findings,” said Jennifer Doherty, investigator and professor of the population health sciences department at the University of Utah.

“This impacts clinical care for individuals with severe endometriosis, since they would benefit from counselling about ovarian cancer risk and prevention.

“This research will also lead to further studies to understand the mechanisms through which specific types of endometriosis cause different types of ovarian cancer.”

However, women with endometriosis should not panic about the findings, researchers noted, because ovarian cancer itself is still rare. About 1.1 per cent of US women will be diagnosed with ovarian cancer at some point in their lifetime, according to the National Cancer Institute.

“Because of the rarity of ovarian cancer, the association with endometriosis only increased the number of cancer cases by 10 to 20 per 10,000 women,” Karen Schliep, senior author of the study and an associate professor in the Division of Public Health at the University of Utah School of Medicine, told CNN.

“We would not recommend, at this point, any change in clinical care or policy. The best way of preventing ovarian cancer is still the recommendation of exercise, not smoking and limiting alcohol.”

Women with endometriosis could pursue surgeries, such as hysterectomies or removal of the ovaries, investigators said. However, since these are invasive procedures, more research is needed to know if these are the right measures, they concluded.

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.